Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Globe Newswire•01/09/2026•07:02 ET
0
Whiz Insights
Get started
Create a free account to read the full story.